Atrial Natriuretic Peptide: A Molecular Target of Novel Therapeutic Approaches to Cardio-Metabolic Disease

• Published in: International journal of molecular sciences Vol. 20; no. 13; p. 3265
• Main Authors: Cannone, Valentina, Cabassi, Aderville, Volpi, Riccardo, Burnett, John C.
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 02.07.2019; MDPI
• Subjects: Animals; Atrial Natriuretic Factor - genetics; Atrial Natriuretic Factor - metabolism; Atrial Natriuretic Factor - pharmacology; Atrial Natriuretic Factor - therapeutic use; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - genetics; Cardiovascular Diseases - metabolism; Genetic Variation; Humans; Insulin resistance; Kinases; Metabolic Diseases - drug therapy; Metabolic Diseases - genetics; Metabolic Diseases - metabolism; Molecular Targeted Therapy; Obesity; Plasma; Review; Studies; United States > US; metabolic syndrome; heart failure; natriuretic peptides; cardiometabolic disease; cGMP; atrial natriuretic peptide; hypertension; obesity; guanylyl cyclase receptor A

Atrial natriuretic peptide (ANP) is a cardiac hormone with pleiotropic cardiovascular and metabolic properties including vasodilation, natriuresis and suppression of the renin-angiotensin-aldosterone system. Moreover, ANP induces lipolysis, lipid oxidation, adipocyte browning and ameliorates insulin...